Organization | Sydney Local Health District

Sydney Local Health District Report issue

Government Phase 1 Phase 2 Phase 3

Founded: Campsie Australia (2005)

Organization Overview

First Clinical Trial

2013

NCT01711125

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Sydney Local Health District

Active Ingredients

Drugs in Phase 3 Trials (3)

baclofen (lioresal) (1 trial)

naltrexone (revia) (1 trial)

topiramate (topamax) (1 trial)

Drugs in Phase 2 Trials (5)

3,4-Methylenedioxymethamphetamine (1 trial)

bivalirudin (angiomax) (1 trial)

niacin (1 trial)

tiopronin (thiola) (1 trial)

unfractionated heparin (1 trial)

Drugs in Phase 1 Trials (1)

cannabidiol (Epidiolex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcoholism (Phase 3)

Liver Diseases (Phase 3)

Liver Diseases, Alcoholic (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 9